

# Pharmacogenetic Treatment with Anti-Glutaminergic Agents for Comorbid PTSD & AUD

Principal Investigators: Bankole Johnson, MD and Melanie Bennett, Ph.D.  
Department of Psychiatry, University of Maryland School of Medicine  
UMB IRB Protocol #: HP-00069465  
Funding Source: National Institute on Alcohol Abuse and Alcoholism

[www.rethinkyourdrinking.org](http://www.rethinkyourdrinking.org)

## Inclusion Criteria

African American men and women

Age 18 to 65 years

Good physical health as determined by study medical history and physical examination

Current DSM-5 diagnosis of PTSD or Other Specified Trauma/Stressor-Related Disorder

Current DSM-5 diagnosis of AUD of moderate or greater severity

Currently drinking  $\geq 21$  alcohol units/week for women and  $\geq 28$  alcohol units/week for men

For women: not currently pregnant/breastfeeding and are currently using contraception

Literate in English

Express a desire to reduce or stop drinking

Willing to participate in a psycho-educational intervention for AUD and PTSD

## Exclusion Criteria

Current DSM-5 psychiatric disorder that warrants treatment (other than PTSD, AUD, or Tobacco Use Disorder)

Severe alcohol withdrawal symptoms that require inpatient treatment

Serious medical comorbidity requiring medical intervention, or any condition that can interfere with the receipt of pregabalin

Received inpatient treatment for alcohol within the last 30 days

Compelled to participate in an alcohol treatment program to maintain liberty

Concurrent treatment with any medications having a potential effect on alcohol consumption

Regular use or misuse of drugs such as opiates, cocaine, amphetamines, barbiturates, or benzodiazepines

History of clinically significant adverse reaction to pregabalin or gabapentin

For more information or questions, please contact  
Brian Brandler (667-214-2003, [bbrandler@som.umaryland.edu](mailto:bbrandler@som.umaryland.edu))